Enzalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer

Enzalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer (Single Technology Assessment)

As part of the NICE single technology appraisal process, the Aberdeen evidence review group (ERG) was commissioned to critically review the company’s submission related to the clinical and cost-effectiveness of Enzalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer. The appraisal is ongoing and NICE are expected to publish guidance in 2020: Enzalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer ID1605. In development [GID-TA10488].

HERU researchers involved in this research project:  Graham Scotland and Daniel Kopasker

External collaborators: Ramsay, C., Brazzelli, M., Cummins, E. and Campbell, M. (Health Services Research Unit (HSRU), University of Aberdeen).